Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$105.55 USD
-0.84 (-0.79%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $105.45 -0.10 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 501 - 512 ( 512 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Presents RET Inhibitor Program BLU-667 Data at AACR, IND Submission Expected 2H:16, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BPMC and Roche to Collaborate on Targeting Kinases in Immuno-Oncology
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q4:15 EPS, BLU-285 Enters Second Ph 1 Study, Data-Rich 2016 Ahead, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
3Q EPS: Systemic Mastocytosis Study Set to Initiate, New Preclinical Programs Revealed, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q2:EPS; Multiple Studies on Track for Initiation in 2015
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
FDA Accepts INDs for Lead Candidates BLU-285 and BLU-554; On Track to Begin Three Ph 1 Trials
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
FDA Accepts INDs for Lead Candidates BLU-285 and BLU-554; On Track to Begin Three Ph 1 Trials
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q1:EPS; Looking to Mid:15 IND Submissions for Lead Product Candidates BLU-285 and BLU-554
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage with an OUTPERFORM Rating and $41 Price Target; A Template for Targeted Therapies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D